Last10K.com

Varian Medical Systems Inc (VAR) SEC Filing 10-Q Quarterly report for the period ending Friday, March 29, 2019

Varian Medical Systems Inc

CIK: 203527 Ticker: VAR

 

Exhibit 99.1

 

Investor Relations Contact

 

J. Michael Bruff

Senior Vice President, Investor Relations

+1 (650) 424-5163

investors@varian.com

 

Press Contact

 

Mark Plungy

Director, Public Relations

+1 (650) 424-5630

mark.plungy@varian.com

 

 

FOR IMMEDIATE RELEASE

 

Varian Reports Results for Second Quarter of Fiscal Year 2019

 

Raises Revenue Guidance for Fiscal Year 2019

  

Second Quarter 2019 Summary

Oncology gross orders grew 15% in dollars, or 18% in constant currency
Total company revenues grew 7% in dollars, or 10% in constant currency, to $779 million
GAAP operating earnings grew 1% at 14.1% of revenues; Non-GAAP operating earnings declined 6% at 15.3% of revenues
GAAP net earnings per diluted share of $0.96; Non-GAAP net earnings per diluted share of $1.05
Recently enacted US/China tariffs negatively impacted revenue growth by $9 million or 120 basis points and GAAP operating earnings growth by $13 million or 160 basis points
Raising revenue growth range for fiscal year 2019 guidance; reaffirming Non-GAAP net earnings per diluted share range of $4.60 to $4.75

 

PALO ALTO, Calif. - April 24, 2019 -

Varian (NYSE: VAR) today announced its second quarter fiscal year 2019 results. All comparisons in this announcement are year-over-year, all quarter and year references are fiscal unless noted otherwise, and any references to orders are gross orders.

 

   

 

 

Summary

 

(Dollars and shares in millions, except per share amounts)  Q2 2019   Q2 2018   Y/Y   1H
FY 2019
   1H
FY 2018
   Y/Y 
Revenues  $779.4   $729.9    7%  $1,520.4   $1,408.4    8%
Gross margin as a percentage of revenues   40.8%   43.6%   (280bps)   41.7%   44.1%   (240bps)
GAAP net earnings (loss) attributable to Varian  $88.6   $73.2    21%  $191.8   $(39.1)   N/M 
GAAP net earnings (loss) per share - diluted  $0.96   $0.79    22%  $2.09   $(0.43)   N/M 
Net cash (used in) provided by operating activities  $(13.4)  $65.5    (120)%  $127.5   $244.5    (48)%
Non-GAAP net earnings (1)  $96.2   $106.7    (10)%  $193.5   $205.1    (6)%
Non-GAAP net earnings per share - diluted (1)  $1.05   $1.15    (9)%  $2.10   $2.21    (5)%
Shares used in computing GAAP net earnings (loss) per diluted share   91.9    92.6         92.0    91.6      
Shares used in computing non-GAAP net earnings per diluted share   91.9    92.6         92.0    92.7      

N/M - Not meaningful

(1)Non-GAAP net earnings and Non-GAAP net earnings per diluted share are defined as GAAP net earnings and GAAP net earnings per diluted share adjusted to exclude the amortization of intangible assets, acquisition-related expenses and benefits, impairment charges, significant litigation charges or benefits and legal costs, gains or losses on equity investments, and significant non-recurring tax expense or benefit.

 

“In the second quarter, we maintained strong momentum,” said Dow Wilson, chief executive officer of Varian. “Each of our geographies delivered exceptional orders growth, including strong double-digit performance in APAC and the seventh consecutive quarter of double-digit growth in EMEA. Based on the company’s results year-to-date and our outlook for the rest of the year, we are raising our fiscal year revenue guidance to 6 to 9 percent while increasing investments in growth priorities such as groundbreaking preclinical research with our FlashForward Consortium.”

 

The company ended the quarter with $546 million in cash and cash equivalents and no debt. Net cash used in operating activities was $13 million, down $79 million due to the tax payments and net working capital impacts from revenue growth. During the quarter, the company invested $51 million to repurchase 420,000 shares of common stock.

 

Oncology Systems Segment

 

In the second quarter, Oncology revenues totaled $747 million, up 7%. Operating earnings for the segment decreased 8%, primarily driven by the impact of tariffs, currency fluctuations and costs related to the ramp of our software deployment capabilities.

 

In the second quarter, Oncology orders were $766 million, up 15%.  Orders in the Americas increased 7% driven by strong U.S. growth. In EMEA, orders rose 17%, the seventh consecutive quarter of double-digit growth for the region. In APAC, orders increased 35%, with accelerating growth in China.

 

   

 

  

Proton Solutions Segment

 

In the second quarter, Proton Solutions revenues totaled $33 million, up 2%. Operating earnings were negatively impacted by $7 million in increased project costs and site delays. 

 

Guidance for Full Fiscal Year 2019

 

The company is raising revenue guidance and are otherwise reaffirming the following guidance for fiscal year 2019:

 

   Prior Guidance  Updated Guidance
Revenues  $3.06 to $3.15 billion  $3.09 to $3.18 billion
Y/Y  5% to 8%  6% to 9%
Non-GAAP operating earnings as a percentage of revenues  17.0% to 18.0%  Unchanged
Non-GAAP net earnings per share – diluted  $4.60 to $4.75  Unchanged
Cash flows from operations  $460 to $510 million  Unchanged

  

This updated guidance reflects increased project costs and site delays in our Proton Solutions business of $7 million, incremental investments in our preclinical research with the FlashForwardTM Consortium of $5 million, and costs related to the ramp of our software deployment capabilities of $2 million, partially offset by an estimated reduction in gross tariff impact of $5 million.

 

The guidance assumes a Non-GAAP effective tax rate of 21% to 22% and a weighted average diluted share count of 92 million, unchanged from our original assumptions. The guidance also assumes currency rates as of the beginning of the fiscal third quarter of 2019, includes the expected net impact of all tariffs effective as of the beginning of the fiscal year, and excludes any future acquisitions.

  

Please refer to “Discussion of Non-GAAP Financial Measures” below for a description of items excluded from expected non-GAAP earnings.

  

Investor Conference Call

 

Varian Medical Systems is scheduled to conduct its second quarter fiscal year 2019 conference call at 1:30 p.m. Pacific Time today. To access the live webcast or replay of the call, visit the Investor Relations page on our website at www.varian.com/investors. To access the call via telephone, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S. The replay can be accessed by dialing 1-877-660-6853 from inside the U.S. or 1-201-612-7415 from outside the U.S. and entering conference ID 13688640. The teleconference replay will be available through 5:00 p.m. Pacific Time, Friday, April 26, 2019.

 

 

# # #

 

   

 

 

About Varian

 

Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter. 

 

 

Forward-Looking Statements

 

Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry or market outlook, including growth drivers; the company’s future orders, revenues, operating expenses, tax rate, cash flows, earnings growth or other financial results; and any statements using the terms “could,” “believe,” “expect,” “promising,” “outlook,” “should,” “well-positioned,” “will” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company’s actual results to differ materially from those anticipated. Such risks and uncertainties include our ability to achieve expected synergies from acquisitions; global economic conditions and changes to trends for cancer treatment regionally; currency exchange rates and tax rates; the impact of the Tax Cuts and Jobs Act; the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; recent and potential future tariffs or a global trade war; demand for and delays in delivery of the company’s products; the company’s ability to develop, commercialize and deploy new products; the company’s ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or procedures; changes in regulatory environments; the company’s assessment of the goodwill associated with its proton solutions business, risks associated with the company providing financing for the construction and start-up operations of particle therapy centers, challenges associated with commercializing the company’s proton solutions business; challenges to public tender awards and the loss of such awards or other orders; the effect of adverse publicity; the company’s reliance on sole or limited-source suppliers; the company’s ability to maintain or increase margins; the impact of competitive products and pricing; the company’s assessment of the goodwill associated with its proton solutions business; the potential loss of key distributors or key personnel; and the other risks listed from time to time in the company’s filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

 

Varian has not filed its Form 10-Q for the quarter ended March 29, 2019. As a result, all financial results described here should be considered preliminary, and are subject to change to reflect any necessary adjustments, or changes in accounting estimates, that are identified prior to the time the company files the Form 10-Q.

  

 

   

 

  

Varian Medical Systems, Inc. and Subsidiaries

Preliminary Condensed Consolidated Statements of Earnings

(Unaudited)

                    

(Dollars and shares in millions, except per share amounts)  Q2 2019   Q2 2018   1H
FY 2019
   1H
FY 2018
 
Gross orders  $770.9   $666.0   $1,492.6   $1,332.1 
Oncology Systems   766.2    664.1    1,482.7    1,284.0 
Proton Solutions   4.7    1.9    9.9    48.1 
Order backlog   3,117.9    2,927.1    3,117.9    2,927.1 
Revenues   779.4    729.9    1,520.4    1,408.4 
Oncology Systems   746.8    698.0    1,449.3    1,347.4 
Proton Solutions   32.6    31.9    71.1    61.0 
Cost of revenues   461.2    411.4    886.1    787.1 
Gross margin   318.2    318.5    634.3    621.3 
As a percentage of revenues   40.8%   43.6%   41.7%   44.1%
Operating expenses                    
Research and development   59.4    58.9    120.3    114.8 
Selling, general and administrative   149.0    139.4    292.5    264.7 
Impairment charges       11.1        11.1 
Operating earnings   109.8    109.1    221.5    230.7 
As a percentage of revenues   14.1%   14.9%   14.6%   16.4%
Interest income, net   3.0    1.3    5.7    2.4 
Other income (expense)   0.2    (14.8)   23.2    (15.0)
Earnings before taxes   113.0    95.6    250.4    218.1 
Taxes on earnings   24.6    22.4    58.1    257.1 
Net earnings (loss)   88.4    73.2    192.3    (39.0)
Less: Net earnings (loss) attributable to non-controlling interests   (0.2)       0.5    0.1 
                     
Net earnings (loss) attributable to Varian  $88.6   $73.2   $191.8   $(39.1)
Net earnings (loss) per share - basic  $0.97   $0.80   $2.11   $(0.43)
                     
Net earnings (loss) per share - diluted  $0.96   $0.79   $2.09   $(0.43)
Shares used in the calculation of net earnings (loss) per share:                    
Weighted average shares outstanding - basic   91.0    91.5    91.0    91.6 
Weighted average shares outstanding - diluted   91.9    92.6    92.0    91.6 

  

   

 

   

Varian Medical Systems, Inc. and Subsidiaries

Preliminary Condensed Consolidated Balance Sheets

(Unaudited)

          

  March 29,   September 28, 
(In millions)  2019   2018 
Assets          
Current assets:          
Cash and cash equivalents  $546.3   $504.8 
Trade and unbilled receivables, net   1,029.2    1,009.9 
Inventories   478.0    438.1 
Prepaid expenses and other current assets   207.7    233.3 
Current assets of discontinued operations       2.3 
Total current assets   2,261.2    2,188.4 
           
Property, plant and equipment, net   268.4    274.6 
Goodwill   309.3    293.6 
Intangible assets   90.8    101.1 
Deferred tax assets   94.9    102.2 
Other assets   365.6    292.8 
Total assets  $3,390.2   $3,252.7 
           
Liabilities and Equity          
Current liabilities:          
Accounts payable  $208.7   $190.3 
Accrued liabilities   352.2    419.7 
Deferred revenues   757.9    729.7 
Total current liabilities   1,318.8    1,339.7 
Other long-term liabilities   331.3    324.3 
Total liabilities   1,650.1    1,664.0 
           
Equity:          
Varian stockholders’ equity:          
Common stock   91.2    91.2 
Capital in excess of par value   813.6    778.1 
Retained earnings   902.3    780.4 
Accumulated other comprehensive loss   (71.8)   (65.3)
Total Varian stockholders’ equity   1,735.3    1,584.4 
Non-controlling interests   4.8    4.3 
Total equity   1,740.1    1,588.7 
Total liabilities and equity  $3,390.2   $3,252.7 

 

   

 

 

Discussion of Non-GAAP Financial Measures

 

This press release includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per diluted share. We define non-GAAP operating earnings as operating earnings excluding amortization of intangible assets, acquisition and integration-related expenses and benefits, impairment charges, and significant litigation charges or benefits and legal costs. These measures are not presented in accordance with, nor are they a substitute for U.S. generally accepted accounting principles, or GAAP. In addition, these measures may be different from non-GAAP measures used by other companies, limiting their usefulness for comparison purposes. The non-GAAP financial measures should not be considered in isolation from measures of financial performance prepared in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. We have provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. We have not provided a reconciliation of non-GAAP guidance measures to the corresponding GAAP measures on a forward-looking basis due to the potential significant variability and limited visibility of the excluded items discussed below.

 

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. Non-GAAP operating earnings and non-GAAP net earnings exclude the following items, except for gain or losses on equity investments, loss on hedges related to acquisition-related activities, and significant non-recurring tax expense or benefit, which are only excluded from non-GAAP net earnings:

 

Amortization of intangible assets: We do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

 

Acquisition and integration-related expenses and benefits: We incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, hedging gains and losses, changes in the fair value of contingent consideration liabilities, gain or expense on settlement of pre-existing relationships, integration costs, breakup fees, etc. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business.

 

Impairment chargesWe incur impairment charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

 

Significant litigation charges or benefits and legal costs: We may incur charges or benefits as well as legal costs from time to time related to litigation and other contingencies. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

 

Gains or losses on equity investments: We may incur gains or losses from the sale of our equity investments in privately-held companies. We do not trade equity investments, and we do not plan on these investments for funding of ongoing operations. We exclude such gains or losses because we do not believe they are reflective of our core business.

 

Significant non-recurring tax expense or benefit: We may incur significant tax expense or benefit as a result of tax legislation and/or a change in judgment about the need for a valuation allowance that are generally unrelated to the level of business activity in the period in which these tax effects are reported. We exclude such expenses or benefits from our non-GAAP net earnings because we believe they do not accurately reflect the underlying performance of our continuing business operations.

 

We apply our GAAP consolidated effective tax rate to our non-GAAP financial measures, other than when the underlying item has a materially different tax treatment.

 

   

 

 

The following table reconciles GAAP and non-GAAP financial measures:

 

Varian Medical Systems, Inc. and Subsidiaries

Reconciliation of Preliminary GAAP and Non-GAAP Financial Measures

(Unaudited)

 

(Dollars and shares in millions, except per share amounts)  Q2 2019   Q2 2018   1H
FY 2019
   1H
FY 2018
 
Non-GAAP adjustments                    
Amortization of intangible assets (1)  $6.1   $3.5   $10.3   $6.6 
Acquisition-related expenses   2.2    3.3    4.6    4.8 
Impairment charge       11.1        11.1 
Litigation charge and legal costs   0.8        1.7     
Other       0.1        0.1 
Total non-GAAP adjustments to operating earnings   9.1    18.0    16.6    22.6 
(Gain) loss on equity investments (2)   0.2        (21.8)    
Loss on hedges related to acquisition-related activities (3)       16.4        16.4 
Tax effects of non-GAAP adjustments   (1.7)   (7.1)   2.1    (8.1)

Significant effects of tax legislation (4)

       6.2    2.3    213.3 
Changes in deferred tax related to an acquisition (5)           2.5     
Total net earnings impact from non-GAAP adjustments  $7.6   $33.5   $1.7   $244.2 
Operating earnings reconciliation                    
GAAP operating earnings  $109.8   $109.1   $221.5   $230.7 
Total operating earnings impact from non-GAAP adjustments   9.1    18.0    16.6    22.6 
Non-GAAP operating earnings  $118.9   $127.1   $238.1   $253.3 
Net earnings (loss) and net earnings (loss) per diluted share reconciliation                    
GAAP net earnings (loss) attributable to Varian  $88.6   $73.2   $191.8   $(39.1)
Total net earnings (loss) impact from non-GAAP adjustments   7.6    33.5    1.7    244.2 
Non-GAAP net earnings attributable to Varian  $96.2   $106.7   $193.5   $205.1 
GAAP net earnings (loss) per share – diluted  $0.96   $0.79   $2.09   $(0.43)
Non-GAAP net earnings per share – diluted  $1.05   $1.15   $2.10   $2.21 
Shares used in computing GAAP net earnings per diluted share   91.9    92.6    92.0    91.6 
Shares used in computing non-GAAP net earnings per diluted share   91.9    92.6    92.0    92.7 

 

(1)Includes $2.9 million, $1.5 million, $4.8 million, and $2.7 million, respectively in cost of revenues for the periods presented.
(2)Primarily includes a $22.0 million gain on the sale of our investment in Augmenix in the year-to-date period 2019.
(3)Represents the hedging loss related to the Australian dollar purchase price for the anticipated Sirtex Medical Limited acquisition.
(4)Represents the tax effect of a change in law related to the U.S. Tax Cuts and Jobs Act. The mandatory deemed repatriation of unremitted foreign earnings resulted in an estimated charge of $2.3 million in the year-to-date period 2019 and $3.7 million in the second quarter of 2018 and $173.1 million in the year-to-date period 2018. The corporate rate reduction resulted in a remeasurement of our deferred tax assets of $2.5 million in the second quarter of 2018 and $40.2 million in the year-to-date period 2018.
(5)Represents the charge to income tax expense due to the increase of a valuation allowance as a result of an acquisition.

 

   

 

 

 


The following information was filed by Varian Medical Systems Inc (VAR) on Wednesday, April 24, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Varian Medical Systems Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Varian Medical Systems Inc.

Continue

Assess how Varian Medical Systems Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Varian Medical Systems Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Other
Filter Subcategory:
All
Product
Earnings
Geography
Expense
Shares
Debt
Other
Inside Varian Medical Systems Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statement Of Equity Statement
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Earnings (Loss)
Condensed Consolidated Statements Of Comprehensive Earnings (Loss) (Parenthetical)
Condensed Consolidated Statements Of Earnings (Loss)
Business Combinations
Business Combinations (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Accrued Product Warranty (Detail)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Lessor Arrangements (Details)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Tables)
Derivative Instruments And Hedging Activities - Additional Information (Detail)
Derivative Instruments And Hedging Activities - Effective Portion Of Foreign Currency Forward Contracts Designated As Cash Flow Hedges (Detail)
Derivative Instruments And Hedging Activities - Gains (Losses) Related To Foreign Currency Forward Exchange Contracts That Are Not Designated As Hedging Instruments (Detail)
Derivative Instruments And Hedging Activities - Outstanding Foreign Currency Forward Contracts That Were Entered Into To Hedge Balance Sheet Exposures (Detail)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Computation Of Net Basic And Diluted Earnings Per Share (Detail)
Employee Stock Plans
Employee Stock Plans (Tables)
Employee Stock Plans - Activity For Restricted Stock, Restricted Stock Units, Deferred Stock Units And Performance Units (Detail)
Employee Stock Plans - Activity Under Employee Stock Plans (Detail)
Employee Stock Plans - Additional Information (Detail)
Employee Stock Plans - Fair Value With Weighted Average Assumptions (Detail)
Employee Stock Plans - Net Share-Based Compensation Expense (Detail)
Fair Value
Fair Value (Tables)
Fair Value - Additional Information (Detail)
Fair Value - Assets And Liabilities Measured At Fair Value On Recurring Basis (Detail)
Fair Value - Reconciliation For Assets And Liabilities Measured And Recorded At Fair Value On Recurring Basis (Detail)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Tables)
Goodwill And Intangible Assets - Activity Of Goodwill By Reportable Operating Segment (Detail)
Goodwill And Intangible Assets - Additional Information (Detail)
Goodwill And Intangible Assets - Future Amortization Expense (Details)
Goodwill And Intangible Assets - Gross Carrying Amount And Accumulated Amortization Of Intangible Assets (Detail)
Income Taxes
Income Taxes - Additional Information (Detail)
Other Financial Information
Other Financial Information (Tables)
Other Financial Information - Cash, Cash Equivalents And Restricted Cash (Details)
Other Financial Information - Components Of Inventories (Detail)
Other Financial Information - Components Of Other Long-Term Liabilities (Detail)
Other Financial Information - Other Income (Expense), Net (Details)
Other Financial Information - Unbilled Receivables And Deferred Revenues From Contracts With Customers (Details)
Other Financial Information - Unfulfilled Performance Obligations (Details)
Proton Solutions Loans And Investments
Proton Solutions Loans And Investments (Tables)
Proton Solutions Loans And Investments - Additional Information (Detail)
Proton Solutions Loans And Investments - Loans And Commitments (Details)
Receivables
Receivables (Details)
Receivables (Tables)
Retirement Plans
Retirement Plans (Tables)
Retirement Plans - Additional Information (Detail)
Retirement Plans - Schedule Of Net Periodic Benefit Costs (Detail)
Segment Information
Segment Information (Tables)
Segment Information - Additional Information (Detail)
Segment Information - Disaggregation Of Revenue (Details)
Segment Information - Operating Results Information For Each Reportable Segment (Detail)
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity - Additional Information (Detail)
Stockholders' Equity - Schedule Of Accumulated Other Comprehensive Earnings (Loss) And Related Tax Effects (Detail)
Stockholders' Equity - Schedule Of Amounts Reclassified Out Of Other Comprehensive Earnings (Detail)
Stockholders' Equity - Shares Repurchased During Period (Details)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Adjustments From Amounts Previously Reported (Details)
Summary Of Significant Accounting Policies Summary Of Significant Accounting Policies (Tables)
Ticker: VAR
CIK: 203527
Form Type: 10-Q Quarterly Report
Accession Number: 0000203527-19-000008
Submitted to the SEC: Wed May 08 2019 12:25:23 PM EST
Accepted by the SEC: Wed May 08 2019
Period: Friday, March 29, 2019
Industry: Electromedical And Electrotherapeutic Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/var/0000203527-19-000008.htm